Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 48.1x - 53.2x | 50.6x |
| Selected Fwd Ps Multiple | 14.4x - 15.9x | 15.1x |
| Fair Value | $35.62 - $39.37 | $37.50 |
| Upside | 21.6% - 34.4% | 28.0% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| bluebird bio, Inc. | - | NasdaqGS:BLUE |
| Vertex Pharmaceuticals Incorporated | - | NasdaqGS:VRTX |
| Geron Corporation | - | NasdaqGS:GERN |
| Incyte Corporation | - | NasdaqGS:INCY |
| BioMarin Pharmaceutical Inc. | - | NasdaqGS:BMRN |
| Agios Pharmaceuticals, Inc. | - | NasdaqGS:AGIO |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| BLUE | VRTX | GERN | INCY | BMRN | AGIO | |||
| NasdaqGS:BLUE | NasdaqGS:VRTX | NasdaqGS:GERN | NasdaqGS:INCY | NasdaqGS:BMRN | NasdaqGS:AGIO | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | NM- | 21.5% | 178.4% | 14.5% | 10.9% | NM- | ||
| 3Y CAGR | 183.9% | 13.3% | 280.9% | 12.4% | 15.6% | NM- | ||
| Latest Twelve Months | 184.1% | 11.7% | 32386.9% | 14.8% | 18.0% | 36.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -4430.5% | 30.3% | -23982.0% | 9.9% | 13.5% | -3975.2% | ||
| Prior Fiscal Year | -718.4% | 36.7% | -77690.7% | 16.2% | 6.9% | -1312.6% | ||
| Latest Fiscal Year | -287.2% | -4.9% | -226.7% | 0.8% | 15.0% | 1845.9% | ||
| Latest Twelve Months | -287.2% | -4.9% | -226.7% | 0.8% | 15.0% | 1845.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -1.7x | 24.1x | -3.7x | 54.2x | 18.7x | -0.5x | ||
| Price / LTM Sales | 0.6x | 11.3x | 13.2x | 2.8x | 4.7x | 46.0x | ||
| LTM P/E Ratio | -0.2x | -232.4x | -5.8x | 359.3x | 31.6x | 2.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.6x | 4.7x | 13.2x | |||||
| Historical LTM P/S Ratio | 46.0x | 68.2x | 155.4x | |||||
| Selected Price / Sales Multiple | 48.1x | 50.6x | 53.2x | |||||
| (x) LTM Sales | 36 | 36 | 36 | |||||
| (=) Equity Value | 1,755 | 1,848 | 1,940 | |||||
| (/) Shares Outstanding | 57.3 | 57.3 | 57.3 | |||||
| Implied Value Range | 30.64 | 32.25 | 33.86 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 30.64 | 32.25 | 33.86 | 29.30 | ||||
| Upside / (Downside) | 4.6% | 10.1% | 15.6% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BLUE | VRTX | GERN | INCY | BMRN | AGIO | |
| Value of Common Equity | 48 | 124,497 | 1,013 | 11,718 | 13,486 | 1,679 | |
| (/) Shares Outstanding | 9.8 | 256.8 | 636.9 | 193.5 | 190.8 | 57.3 | |
| Implied Stock Price | 4.88 | 484.82 | 1.59 | 60.55 | 70.69 | 29.30 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4.88 | 484.82 | 1.59 | 60.55 | 70.69 | 29.30 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |